(Bloomberg) With weight-loss drugs that reduce the risk of heart attacks and diabetes potentially improving millions of lives, stock investors have had the somewhat unpleasant task of sussing out the impact on a host of health-care companies.Most Read from BloombergPakistan Rupee Set to Become Top Performing Currency Globally Europe’s Richest Royal Family Builds $300 Billion Finance EmpireTop Chinese Scientist Claims India Moon Landing Nowhere Near South PoleUAW Aims For At Least 30% Wage Bum
Weight-Loss Drugs Divide Wall Street on Medical Device Stocks bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
(Bloomberg) Novo Nordisk A/S shares fell on Wednesday in the first trading session following a split aimed at increasing the liquidity of the Danish drugmaker’s soaring stock.Most Read from BloombergLuxury Cruise Ship Full of Australians Stuck in Greenland ArcticiPhone Pro’s Titanium Finish Stands Out in First Look at DeviceChina Flags ‘Security Incidents’ With Apple’s iPhonesApple’s iPhone 15 Debut Includes Higher Price on Top ModelAT&T, T-Mobile Offer Free iPhone 15 in Lure for New Subscrib
Doctors are getting excited about new hormonal treatments for obesity that may even be more effective than Ozempic, according to early-stage clinical trials.